Your browser doesn't support javascript.
Herbal medicines in the treatment of coronavirus disease 2019 (Covid-19)
Journal of Nephropharmacology ; 10(2) (no pagination), 2021.
Article in English | EMBASE | ID: covidwho-2304828
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus, started in livestock within the markets of Wuhan, China and was consequently spread around the world. The virus has been rapidly spread worldwide due to the outbreak. COVID-19 is the third serious coronavirus outbreak in less than 20 years after Severe Acute Respiratory Syndrome (SARS) in 2003 and Middle East Respiratory Syndrome (MERS) in 2012. The novel virus has a nucleotide identity closer to that of the SARS coronavirus than that of the MERS coronavirus. Since there is still no vaccine, the main ways to improve personal immunity against this disease are prophylactic care and self-resistance including an increased personal hygiene, a healthy lifestyle, an adequate nutritional intake, a sufficient rest, and wearing medical masks and increasing time spent in well ventilated areas. There is a need for novel antivirals that are highly efficient and economical for the management and control of viral infections when vaccines and standard therapies are absent. Herbal medicines and purified natural products have the potential to offer some measure of resistance as the development of novel antiviral drugs continues. In this review, we evaluated 41 articles related to herbal products which seemed to be effective in the prevention or treatment of COVID-19.Copyright © 2021 The Author(s).
Keywords
Angiotensin-converting enzyme 2; Coronavirus disease 2019; covid-19; Flavonoids; Herbal medicines; antiviral activity; asthma/dt [Drug Therapy]; clinical effectiveness; coronavirus disease 2019/dt [Drug Therapy]; coughing/dt [Drug Therapy]; dyspnea/dt [Drug Therapy]; human; infection control; infection prevention; medicinal plant; Middle East respiratory syndrome; molecular model; nonhuman; preventive medicine; protein targeting; review; severe acute respiratory syndrome; virus replication; abacavir/ct [Clinical Trial]; abacavir/dt [Drug Therapy]; angiotensin converting enzyme 2/ec [Endogenous Compound]; C reactive protein/ec [Endogenous Compound]; Chinese drug/ct [Clinical Trial]; Chinese drug/dt [Drug Therapy]; Chinese drug/pd [Pharmacology]; emodin/ct [Clinical Trial]; emodin/dt [Drug Therapy]; emodin/pd [Pharmacology]; glucocorticoid/ct [Clinical Trial]; glucocorticoid/dt [Drug Therapy]; herbaceous agent/ct [Clinical Trial]; herbaceous agent/dt [Drug Therapy]; herbaceous agent/pd [Pharmacology]; hydroxychloroquine/ct [Clinical Trial]; hydroxychloroquine/dt [Drug Therapy]; interferon/ct [Clinical Trial]; interferon/dt [Drug Therapy]; interleukin 6/ec [Endogenous Compound]; interleukin 6 inhibitor/ct [Clinical Trial]; interleukin 6 inhibitor/dt [Drug Therapy]; interleukin 8/ec [Endogenous Compound]; lopinavir plus ritonavir/ct [Clinical Trial]; lopinavir plus ritonavir/dt [Drug Therapy]; oseltamivir/ct [Clinical Trial]; oseltamivir/dt [Drug Therapy]; pseudoephedrine/ct [Clinical Trial]; pseudoephedrine/dt [Drug Therapy]; remdesivir/ct [Clinical Trial]; remdesivir/dt [Drug Therapy]; ribavirin/ct [Clinical Trial]; ribavirin/dt [Drug Therapy]; thalidomide/ct [Clinical Trial]; thalidomide/dt [Drug Therapy]; tocilizumab/ct [Clinical Trial]; tocilizumab/dt [Drug Therapy]; tumor necrosis factor/ec [Endogenous Compound]; umifenovir/ct [Clinical Trial]; umifenovir/dt [Drug Therapy]

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Traditional medicine Language: English Journal: Journal of Nephropharmacology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Traditional medicine Language: English Journal: Journal of Nephropharmacology Year: 2021 Document Type: Article